Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

BRIEF-Roche CEO says $4.3 Bln Spark Deal "Goes Beyond Haemophilia A"

Published 2019-02-25, 06:11 a/m
© Reuters.  BRIEF-Roche CEO says $4.3 Bln Spark Deal "Goes Beyond Haemophilia A"
NOVN
-
ROG
-
PFE
-

Feb 25 (Reuters) - Roche Holding Ag ROG.S :

* CEO SAYS HAEMOPHILIA GENE THERAPY IS AN IMPORTANT PART OF SPARK ACQUISITION, BUT THAT DEAL "GOES BEYOND HAEMOPHILIA A" TO REST OF PORTFOLIO

* CEO SAYS FEELS NOW IS THE RIGHT TIME TO "STEP UP" AND EXTEND PORTFOLIO INTO GENE THERAPY

* CEO SAYS SEES HAEMOPHILIA GENE THERAPY, HEMLIBRA ARE COMPLEMENTARY PRODUCTS

* CEO SAYS ROCHE CONVINCED STEROID PROPHYLAXIS SUFFICIENT TO MITIGATE IMMUNE RESPONSE OBSERVED IN HAEMOPHILIA A GENE THERAPY FROM SPARK

* CEO SAYS DOES NOT SEE PRICING BENEFIT TO HAVING BOTH GENE THERAPY, HEMLIBRA FOR HAEMOPHILIA A

* CEO SAYS MUST FIND "SUSTAINABLE REIMBURSEMENT SCHEMES" FOR ONE-TIME GENE THERAPY, INCLUDING THE INTRODUCTION OF ANNUITIES BASED ON EFFICACY

* CEO SAYS SPARK'S HAEMOPHILIA A GENE THERAPY HAS POTENTIAL TO BE "BEST IN CLASS" BASED ON CLINICAL TRIALS, SAYS REST OF PORTFOLIO IS "DIFFERENTIATED"

* CEO SAYS SPARK DEALS WITH NOVARTIS NOVN.S , PFIZER PFE (NYSE:PFE).N WILL CONTINUE AFTER ROCHE ACQUISITION

* CEO SAYS GENE THERAPY CONTRIBUTIONS TO SALES WILL DEPEND ON SPARK PIPELINE EVOLUTION

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.